+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Asia Pacific Human Papillomavirus Vaccine Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Dosage, Age, Application, and End User- Product Image
Asia Pacific Human Papillomavirus Vaccine Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Dosage, Age, Application, and End User- Product Image
Sale

Asia Pacific Human Papillomavirus Vaccine Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Dosage, Age, Application, and End User

  • PDF Icon

    Report

  • 181 Pages
  • September 2022
  • Region: Asia Pacific
  • The Insight Partners
  • ID: 5668510
UP TO OFF until Dec 31st 2024
Description Jump to:
The APAC human papillomavirus (HPV) vaccine market is expected to grow from US$ 567.57 million in 2022 to US$ 826.34 million by 2028; it is estimated to grow at a CAGR of 6.5% from 2022 to 2028.

Companies are undertaking many research and development activities to introduce advanced HPV tests. For instance, in May 2021, BD, a leading medical technology company, launched the first CE-marked assay for HPV screening from at-home self-collected vaginal samples. This allows laboratories to process self-collected samples via a BD diluent tube. At-home collection of samples will help address the urgent public health challenge of reaching out to women who do not attend routine cervical cancer screening. Further, in September 2020, drug administrations across the region approved the expanded use of F. Hoffmann-La Roche Ltd, CINtec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). The CINtec PLUS Cytology test identifies the simultaneous presence of the two biomarkers -- p16 and Ki-67 in a single cell. This abnormality is associated with HPV infections that progress to pre-cancer or cancer if not treated. A positive result of these two biomarkers is more significantly at risk for disease. Such robust developments in HPV diagnostics tests are likely to reshape the HPV vaccines market during the forecast period.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC human papillomavirus (HPV) vaccine market . The APAC human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.

APAC Human Papillomavirus (HPV) Vaccine Market Segmentation

The APAC human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country.
  • Based on type, the APAC human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment dominated the market in 2022.
  • Based on dosage, the APAC human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment dominated the market in 2022.
  • Based on age, the APAC human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment dominated the market in 2022.
  • Based on application, the APAC human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment dominated the market in 2022.
  • Based on end user, the APAC human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment dominated the market in 2022.
  • Based on country, the APAC human papillomavirus (HPV) vaccine market has been categorized into China, Japan, India, Australia, Southeast Asia, New Zealand, South Korea, and the Rest of APAC. China would dominate the market in 2022.
ChengDu Institute of Biological Products Co., Ltd.; GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; Vaccitech; Walvax Biotechnology Co., Ltd.; and Xiamen Innovax Biotech CO., LTD. are among the leading companies in the APAC human papillomavirus (HPV) vaccine market.

Table of Contents

1. Introduction
1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 APAC Human Papillomavirus (HPV) Vaccines Market - By Type
1.3.2 APAC Human Papillomavirus (HPV) Vaccines Market - By Dosage
1.3.3 APAC Human Papillomavirus (HPV) Vaccines Market - By Age
1.3.4 APAC Human Papillomavirus (HPV) Vaccines Market - By Application
1.3.5 APAC Human Papillomavirus (HPV) Vaccines Market - By Distribution Channel
1.3.6 APAC Human Papillomavirus (HPV) Vaccines Market - By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. APAC Human Papillomavirus (HPV) Vaccine Market - Market Landscape
4.1 Overview
4.2 APAC PEST Analysis
4.3 Experts Opinion
5. APAC Human Papillomavirus (HPV) Vaccine Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Prevalence of HPV Associated Diseases
5.1.2 Initiatives Taken by Health Organizations
5.2 Market Restraints
5.2.1 High Cost of HPV Vaccines
5.3 Market Opportunities
5.3.1 Growing Number of HPV Awareness Programs
5.4 Future Trends
5.4.1 Advancements in HPV Diagnostics Tests
5.5 Impact Analysis
6. Human Papillomavirus (HPV) Vaccine Market- APAC Analysis
6.1 APAC Human Papillomavirus (HPV) Vaccine Market Revenue Forecast and Analysis
7. APAC Human Papillomavirus (HPV) Vaccine Market Analysis - By Type
7.1 Overview
7.2 By Type: Market Revenue and Forecast Analysis (US$ Million)
7.3 9-valent HPV vaccine
7.3.1 Overview
7.3.2 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
7.4 Quadrivalent HPV vaccine
7.4.1 Overview
7.4.2 Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
7.5 Bivalent HPV Vaccine
7.5.1 Overview
7.5.2 Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)
8. APAC Human Papillomavirus (HPV) Vaccine Market Analysis - By Dosage
8.1 APAC Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)
8.2 2 Dose
8.2.1 Overview
8.2.2 2 Dose: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
8.3 3 Dose
8.3.1 Overview
8.3.2 3 Dose: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
9. APAC Human Papillomavirus (HPV) Vaccine Market Analysis - By Age
9.1 APAC Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)
9.2 9 to 14 Years
9.2.1 Overview
9.2.2 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
9.3 to 45 Years
9.3.1 Overview
9.3.2 to 45 Years: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
10. APAC Human Papillomavirus (HPV) Vaccine Market Analysis - By Application
10.1 APAC Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)
10.2 HPV-attributable Cancer
10.2.1 Overview
10.2.2 HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
10.3 Genital Warts
10.3.1 Overview
10.3.2 Genital Warts: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
11. APAC Human Papillomavirus (HPV) Vaccine Market Analysis - By End User
11.1 Overview
11.2 APAC Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)
11.3 Doctor Office
11.3.1 Overview
11.3.2 Doctor Office Market Revenue and Forecast to 2028 (US$ Million)
11.4 Community Health Clinics
11.4.1 Overview
11.4.2 Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)
11.5 School-based Health Centers
11.5.1 Overview
11.5.2 School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)
11.6 Health Departments
11.6.1 Overview
11.6.2 Health Departments Market Revenue and Forecast to 2028 (US$ Million)
11.7 Hospitals
11.7.1 Overview
11.7.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)
11.8 Others
11.8.1 Overview
11.8.2 Others Market Revenue and Forecast to 2028 (US$ Million)
12. APAC Human Papillomavirus (HPV) Vaccine Market - Country Analysis
12.1 Overview
12.1.1 APAC: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Country (2022 & 2028)
12.1.1.1 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.1.1 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.1.2 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.1.1.1.3 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.1.1.1.4 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.1.1.1.5 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.1.1.1.6 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.1.1.2 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.2.1 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.2.2 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.1.1.2.3 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.1.1.2.4 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.1.1.2.5 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.1.1.2.6 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.1.1.3 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.3.1 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.3.2 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.1.1.3.3 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.1.1.3.4 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.1.1.3.5 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.1.1.3.6 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.1.1.4 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.4.1 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.4.2 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.1.1.4.3 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.1.1.4.4 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.1.1.4.5 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.1.1.4.6 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.1.1.5 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.5.1 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.5.2 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.1.1.5.3 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.1.1.5.4 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.1.1.5.5 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.1.1.5.6 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.1.1.6 New Zealand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.6.1 New Zealand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.6.2 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.1.1.6.3 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.1.1.6.4 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.1.1.6.5 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.1.1.6.6 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.1.1.7 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.7.1 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.7.2 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.1.1.7.3 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.1.1.7.4 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.1.1.7.5 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.1.1.7.6 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.1.1.8 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.8.1 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.8.2 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.1.1.8.3 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.1.1.8.4 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.1.1.8.5 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.1.1.8.6 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.1.1.9 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.9.1 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.9.2 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.1.1.9.3 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.1.1.9.4 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.1.1.9.5 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.1.1.9.6 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.1.1.10 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.10.1 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.10.2 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.1.1.10.3 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.1.1.10.4 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.1.1.10.5 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.1.1.10.6 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.1.1.11 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.11.1 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.11.2 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.1.1.11.3 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.1.1.11.4 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.1.1.11.5 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.1.1.11.6 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
12.1.1.12 Rest of APAC: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.12.1 Rest of APAC: Human Papillomavirus (HPV) Vaccines Market- Revenue and Forecast to 2028 (US$ Million)
12.1.1.12.2 Rest of APAC: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)
12.1.1.12.3 Rest of APAC: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)
12.1.1.12.4 Rest of APAC: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)
12.1.1.12.5 Rest of APAC: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)
12.1.1.12.6 Rest of APAC: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)
13. Industry Landscape
13.1 Overview
13.2 Inorganic Growth Strategies
13.2.1 Overview
13.3 Organic Growth Strategies
13.3.1 Overview
14. Company Profiles
14.1 Merck & Co., Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 GlaxoSmithKline plc.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 INNOVAX Xiamen Innovax Biotech CO., LTD.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Serum Institute of India Pvt. Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Walvax Biotechnology Co., Ltd.
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Inovio Pharmaceuticals
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Vaccitech
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 ChengDu Institute of Biological Products Co., Ltd.
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Sanofi
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 R-Pharm
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About the Publisher
15.2 Glossary of Terms

Companies Mentioned

  • ChengDu Institute of Biological Products Co., Ltd.
  • GlaxoSmithKline plc.
  • Inovio Pharmaceuticals
  • Merck & Co., Inc.
  • R-Pharm
  • Sanofi
  • Serum Institute of India Pvt. Ltd
  • Vaccitech
  • Walvax Biotechnology Co., Ltd.
  • Xiamen Innovax Biotech CO., LTD.

Table Information

Report AttributeDetails
No. of Pages181
PublishedSeptember 2022
Forecast Period2022 - 2028
Estimated Market Value ( USD ) in 2022 $ 567.57 Million
Forecasted Market Value ( USD ) by 2028 $ 826.34 Million
Compound Annual Growth Rate6.5%
Regions CoveredAsia Pacific
No. of Companies Mentioned10

Related Topics

Related Reports

Human Papillomavirus Vaccine Market by Disease Indication, Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Human Papillomavirus Vaccine Market by Disease Indication, Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Human Papillomavirus Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Human Papillomavirus Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 140 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccine Global Market Report 2024 - Product Image

Human Papillomavirus (HPV) Vaccine Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccine Market Report and Forecast 2024-2032 - Product Image

Human Papillomavirus (HPV) Vaccine Market Report and Forecast 2024-2032

  • Report
  • 250 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Human Papillomavirus (HPV) Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.